SCHEMBL20150233

SCHEMBL20150233

Cc1nc2c(Cl)cc(Cl)cc2n1C1CCCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 2/20 0.43
CDK9 P50750 2/20 0.43
YTHDC1 Q96MU7 1/20 0.42
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
CYP2C19 P33261 1/20 0.33
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
GFER P55789 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14723198 0.88 CCNT1 (0.39) CCNT1CDK9YTHDC1RXRARXRB
SCHEMBL14723439 0.85 PIK3C2B (0.37) CCNT1CDK9YTHDC1RXRARXRB
SCHEMBL14723450 0.84 YTHDC1 (0.36) CCNT1CDK9YTHDC1RXRARXRB
SCHEMBL20091689 0.80 YTHDC1 (0.40) CCNT1CDK9YTHDC1RXRARXRB
SCHEMBL20092629 0.74 YTHDC1 (0.45) CCNT1CDK9YTHDC1RXRARXRB
SCHEMBL22411531 0.74 YTHDC1 (0.46) CCNT1CDK9YTHDC1MEN1KMT2A
SCHEMBL23171987 0.72 YTHDC1 (0.39) CCNT1CDK9YTHDC1MEN1KMT2A
SCHEMBL14964663 0.72 CYP2C19 (0.45) CCNT1CDK9YTHDC1MEN1KMT2A
SCHEMBL29877869 0.72 CYP2C19 (0.45) CCNT1CDK9YTHDC1MEN1KMT2A
SCHEMBL19050034 0.72 YTHDC1 (0.45) YTHDC1MEN1KMT2ACYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CCNT1 3794/4885CDK9 194/4885YTHDC1 2051/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 CCNT1 3794/4885CDK9 194/4885YTHDC1 2051/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 CCNT1 3794/4885CDK9 194/4885YTHDC1 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.